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Analysis of drug efflux. Cells grown in RPMI-1640 medium containing 10% fetal bovine serum were centrifuged and suspended in glucose-free EF medium containing 10 mM sodium azide. EF medium is composed of 20 mM Tris-HCl (pH 7.6), 0.14 M NaCl, 5.0 mM KC1, 1.0 mM CaCl 2 , 0.5 mM MgCl 2 , 2 mM glutamine, 1.8 mM NaH 2 PO 4 , 5.6 mM Na 2 HPO 4 , 1 x concentration of Eagle's MEM amino acids and vitamins, and 2% fetal bovine serum. The cells were thereafter incubated with [ 3 H]daunomycin (600 cpm/ng) for 30 minutes at 37 °C. At the end of this time period, the cells were centrifuged, suspended in EF medium containing 15 mM glucose, and incubated at 37 *C in the absence or presence of ATPase inhibitor. After various time periods, aliquots were centrifuged, and the amount of radioactivity contained in the cell pellet was determined.
Binding of azidopine to P-glycoprotein. Binding of the photoactive agent [
3 H]azidopine to P-glycoprotein was carried out as described previously (13).
Results

Effect of Bafilomycin A,
We examined the effect of bafilomycin A, on [ 3 H]daunomycin accumulation in HL60 cells isolated for resistance to either doxorubicin or vincristine (10,11). During a 3-hour incubation period, bafilomycin A, (4.4 \JLM) did not affect drug levels in sensitive cells (Fig. 1, A) . In contrast, bafilomycin A! at this same concentration induced a major increase in cellular drug levels in both the HL60/Adr cells (Fig. 1, B) and the HL60/Vinc cells (Fig. 1, C) . Bafilomycin A, was particularly active against HL60/Vinc cells, and within 30 minutes the levels of drug accumulation in the presence of this agent were comparable to those found in drugsensitive cells. The levels of [ 3 H]daunomycin uptake in HL60/Adr cells treated with bafilomycin A, were about 60% of those found in drug-sensitive cells.
We also examined the effect of various concentrations of bafilomycin A, on drug accumulation in resistant cells (Fig. 2) . In (Fig. 3, A) and HL60/Vinc cells (Fig. 3, B) .
Effect of Other H + -ATPase Inhibitors
We have also examined the effect of a variety of H + -ATPase inhibitors on drug accumulation in sensitive and resistant cells. The results showed that vanadate and ouabain, which are selective for EIEJtype ATPase activity (79^0), had either no effect (HL60/Adr) or only a slight effect (HL60/Vinc) on drug accumulation (Table 1) . Similarly, in glucose-containing medium, azide-an inhibitor of F,F O mitochondrial ATPase (1920)-did not affect drug levels in either the HL60/Adr isolate or the HL60/Vinc isolate (Table  1) . For reasons that are not known, oligomycin, which also inhibits F,F O mitochondrial ATPase activity, enhanced drug accumulation in HL60/Vinc cells but not in HL60/Adr cells (Table 1) . Drug uptake studies were also carried out in the presence of 7-chloro-4-nitrobenz-2-oxa 1,3 diazole, an agent capable of inhibiting vacuolar H + -ATPase, F,F 0 mitochondrial ATPase, and other ATPases as well (Table 1 ) (1920) . The results showed that this agent induced a major increase in drug accumulation (Table 1) and was ef- tNos. in parentheses refer to increase (-fold) in drug accumulation relative to that which occurs in the absence of ATPase inhibitor. Each experiment was conducted at least twice with very little variation in the results obtained.
Jin glucose-containing medium.
fective in inhibiting drug efflux in both HL60/Adr cells (Fig. 3, A) and HL60/Vinc cells (Fig. 3, B) . In view of the results obtained with selective inhibitors of F,F 0 and EIEJ ATPases, it can be suggested that the effect of 7-chloro-4-nitrobenz-2-oxa 1,3 diazole on drug accumulation occurs as a result of an inhibition of vacuolar H + -ATPase activity. In parallel experiments, we observed that none of the agents described above at the concentrations used affected drug levels in sensitive cells (data not shown).
Additional experiments were carried out to determine if bafilomycin A, serves as a substrate for P-glycoprotein. In these studies, we examined the ability of bafilomycin A, to compete with [ 3 H]azidopine binding to P-glycoprotein (13). The results showed that concentrations of bafilomycin A, (2-4 \iM) which induced a major increase in drug accumulation in HL60/Vinc cells had no effect on the binding of azidopine to P-glycoprotein (data not shown). Similar experiments could not be conducted with PI90, a protein associated with drug resistance in HL60/Adr cells, since previous studies have not detected any agent capable of binding to this protein (13).
Discussion
HL60/Vinc cells contain high levels of P-glycoprotein, a protein which would be expected to contribute to drug efflux in this isolate (22) . A similar drug-binding protein has not been found in HL60/Adr cells (13). These cells do, however, contain increased levels of a 190-kd (PI90) adenosine triphosphate-binding protein which has a minor sequence homology with P-glycoprotein (23). P190 may contribute to drug resistance in this isolate. In the present study, we found evidence that vacuolar H + -ATPase plays an important role in the pathway of drug efflux from both HL60/Adr cells and HL60/Vinc cells. This evidence is based on the finding that bafilomycin A,, a selective inhibitor of this type of enzyme activity (21), induces a major increase in drug accumulation and also inhibits efflux in both resistant isolates. 7-Chloro-4-nitrobenz-2-oxa 1,3 diazole, which is also capable of inhibiting vacuolar H + -ATPase activity, induces an effect similar to that of bafilomycin A,. Our experiments with a variety of other ATPase inhibitors suggest that neither EiEj-type ATPase nor FjFo-type ATPase has any major involvement in the drug efflux pathway. In the absence of glucose, azide, which is an inhibitor of F,F 0 mitochondrial ATPase, induces an increase in drug accumulation. This finding suggests that under these conditions, adenosine triphosphate generated during oxidative phosphorylation serves as an energy source for drug efflux.
The mechanism by which vacuolar H + -ATPase contributes to drug efflux is not known. In the cell, these enzymes function at a number of endomembrane sites, such as the endoplasmic reticulum, Golgi complex, endosomes, and lysosomes, where they contribute to intraorganelle pH (1920) . Recent studies have also provided evidence that a vacuolar H + -ATPase is present in the macrophage plasma membrane and at this site contributes to the regulation of cytoplasmic pH by extruding H + (24). Certain lines of evidence (3,4) suggest that P-glycoprotein functions at the plasma membrane, where it binds the incoming drug and thereby extrudes this material to the outside of the cell. If that is the case, and a vacuolar H + -ATPase is present in the plasma membrane of resistant cells, the activity of this enzyme may be coupled to the activity of P-glycoprotein.
It has also been proposed that drug efflux in P-glycoprotein-containing cells occurs via a pathway whereby drugs are trapped in acidic vesicles, which are thereafter removed from the cell by exocytosis (17,18) . Some evidence for this hypothesis has been provided by other studies which report that agents such as monensin and nigericin, which block secretory processes (25), increase drug accumulation and inhibit drug efflux (26-25). Nigericin and monensin are also capable of altering the activity of vacuolar H + -ATPase (29JO) and can alkalinize acidic vesicles. Evidence has also been obtained that resistant cells contain increased levels of adsorptive endocytosis, which suggests the possibility that drugs become trapped in endosomes and are removed via the endosomelysosome pathway (18). Resistant cells may thus have a mechanism for transporting drugs into vesicles, and the vacuolar H + -ATPase may be essential for maintaining an acidic environment within these organelles. Many drugs associated with multidrug resistance would be protonated under these conditions and would become trapped in the vesicular compartment In sensitive cells, drugs may move directly to the nucleus where they would exert cytotoxic effects. It is not known if a relationship exists between the possible involvement of vacuolar H + -ATPase in efflux in the P-glycoproteincontaining HL60/Vinc cells and this same process in the P-glycoprotein-negative isolate HL60/Adr. These two isolates may possibly contain a common pathway for drug efflux, which requires vacuolar H + -ATPase activity. Of interest is a study suggesting that membrane vesicles may contribute to efflux in HL60/Adr cells (31) . Further studies to elucidate the involvement of vacuolar H + -ATPase activity in drug resistance could be important in establishing rational strategies for reversing the resistant phenotype.
